Pancreatic Ductal Adenocarcinoma (PDAC) Clinical Trials in Tampa, Florida

8 studies are recruiting for pancreatic ductal adenocarcinoma (pdac) in Tampa, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)

   This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of [¹⁸F]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed pancreatic ductal adenocarcinoma. Following screening, using a standardized administration pr…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Moffit Cancer Center, Tampa, Florida

   Locations

   16 in total

   Run by

   SOFIE

   See if you can join NCT07217717 on ClinicalTrials.gov

2. Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

   The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

   Locations

   49 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07491445 on ClinicalTrials.gov

3. Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

   The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Locations

   9 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07621718 on ClinicalTrials.gov

4. Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

   The purpose of this study is to evaluate the efficacy of combination therapy with two investigational RAS(ON) inhibitors (daraxonrasib and zoldonrasib) compared to chemotherapy.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07805954 on ClinicalTrials.gov

5. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

   This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Locations

   29 in total

   Run by

   Verastem, Inc.

   See if you can join NCT07644559 on ClinicalTrials.gov

6. Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens

   The goal of this clinical study is to evaluate whether the NEO-Match® test, based on ARTIDIS nanomechanical profiling technology, can help predict treatment outcomes and improve clinical decision-making in patients with suspected pancreatic cancer undergoing biopsy. The main questions this study ai…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Run by

   ARTIDIS AG

   See if you can join NCT07542041 on ClinicalTrials.gov

7. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

   This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Lee Moffitt Cancer Center, Tampa, Florida

   Locations

   17 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06040541 on ClinicalTrials.gov

8. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

   Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Locations

   21 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT05379985 on ClinicalTrials.gov